Black Diamond Therapeutics, Inc. (BDTX) Dividend History

Black Diamond Therapeutics, Inc. (BDTX) is a biotechnology company focused on developing precision oncology medicines. It utilizes its unique oncology master key platform to identify and target specific genetic mutations in cancer, aiming to deliver personalized treatment options for patients with difficult-to-treat tumors.

One Main Street, 14th Floor, Cambridge, MA, 02142
Phone: 617-417-5868
Website: https://www.blackdiamondtherapeutics.com

Dividend History

Black Diamond Therapeutics, Inc. currently does not pay dividends

Company News

Black Diamond (BDTX) Q2 Loss Narrows 47%

Black Diamond Therapeutics reported a narrower net loss in Q2 2025, with improved operational efficiency and focus on silevertinib clinical development. The company completed Phase 2 trial enrollment and maintains a cash runway through Q4 2027.

The Motley Fool
Servier and Black Diamond Therapeutics Announce Global Licensing Agreement for BDTX-4933, A Targeted Oncology Therapy

Servier and Black Diamond Therapeutics have announced a global licensing agreement for BDTX-4933, a targeted oncology therapy in Phase 1 development. Servier will lead the development and commercialization of the therapy, with Black Diamond receiving an upfront payment and potential milestone and royalty payments.

GlobeNewswire Inc.
Should You Buy Black Diamond Therapeutics (BDTX) Ahead of Earnings?

Black Diamond Therapeutics (BDTX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Zacks Investment Research
Wall Street Breakfast: The Week Ahead

Stay informed with the latest financial news and updates.

Seeking Alpha

Featured Companies: AYI BB CAG CALM CARM DIS DJT EME GBX ILMN KLG LEVI LGCL LNN LW NEO PAYX PLAY PVH RDDT RYDE SFWL SIRI SPWH TSLA ZVIA
Black Diamond Therapeutics And 2 Other Stocks Under $3 Insiders Are Buying

The Dow Jones closed lower by around 250 points on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform. Black Diamond Therapeutics The Trade: Black Diamond Therapeutics, Inc. (NASDAQ: BDTX) 10% owner BB Biotech AG acquired a total of 400,000 shares an average price of $2.34. To acquire these shares, it ...Full story available on Benzinga.com

Benzinga

Page data last updated 09/07/2025 04:12:39 UTC